Aberrant FGFR2 signaling has been linked to tumorigenesis in several cancers, including breast, gastric, and endometrial cancers, through the activation of downstream pathways such as MAPK, PI3K/AKT, and STAT signaling cascades. The gene discussed is AKT1; the disease is endometrial cancer.